临床试验：克唑替尼在IB-IIIA期非小细胞肺癌手术切除及ALK融合突变治疗中的应用

This phase III ALCHEMIST trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.

这个III期临床试验研究克唑替尼在IB-IIIA期非小细胞肺癌患者中的作用如何，该非小细胞肺癌已经通过手术切除，并且具有称为间变性淋巴瘤激酶（ALK）的蛋白质的突变。ALK的突变或改变可以使其对肿瘤细胞的生长和进展非常活跃和重要。Crizotinib可能通过阻断ALK蛋白的作用而阻止肿瘤细胞的生长。Crizotinib可能是治疗非小细胞肺癌和ALK融合突变的有效药物。